The Evidence & Validation framework isn’t about marketing slides. It’s about reading a vendor through their actual clearance record, and you do this before you ever look at a pitch deck. HeartFlow, Tempus AI, and Butterfly Network are good examples of companies that operate this way. They’re in a recorded set where materials are built on cleared regulatory routes, not just hopeful product promises. FDA Regulatory Clearance is the non-negotiable first filter in this frame, and our Clinical Evidence Scoring is just the methodology for turning those dense regulatory paper trails into signals you can actually compare.
Why Regulatory Clearance is Your First Filter
FDA Regulatory Clearance gives you a verifiable signal on any healthcare AI solution, and you can access it long before you ever have to sit through a vendor demo. The whole point of the clearance process is to establish a baseline for safety and effectiveness. As of September 2026, the FDA has authorized over 1,600 AI/ML medical devices, a number that exploded from a mere 6 devices in 2015 to 335 in 2025 alone FDA AI Medical Devices authorized statistics.
- A whopping 94.6% of these devices got cleared through the 510(k) pathway.
- Only 5.4% went through the more rigorous De Novo pathway.
- Radiology still dominates, accounting for 76% of all cleared AI devices.
The fact that most clearances are 510(k) means most of these tools are just proving “substantial equivalence” to a device that’s already on the market. It doesn’t always mean the company has done its own independent clinical validation, which should raise some serious safety questions about this rapid growth on what is often very thin evidence. In fact, a JAMA Network Open analysis found a 4.8% recall rate among FDA-cleared AI devices, involving 43 out of 903 devices they looked at. The median time before a recall was issued was 458 days, and what’s worse, only 9% of FDA-approved AI devices even have post-market surveillance programs AI Device Recall Rate and Post-Market Surveillance. The data was clear: devices that got cleared without published clinical studies had a much higher risk of being recalled.
Turning Paper Trails into a Scorecard
Clinical Evidence Scoring is our method for converting that messy regulatory paper trail into a comparable signal. The methodology looks at the FDA clearance type, the volume and quality of peer-reviewed publications, and any randomized controlled trial (RCT) evidence. We also factor in real-world deployment data and post-market surveillance. It’s a framework that ranks companies across five tiers. Hello Heart, for example, is a Tier 1 company, a rank it earned through multi-site peer-reviewed publications and a collaboration with the ACC. Its clinical validation includes over 6 peer-reviewed publications covering more than 28,000 participants, which is the kind of concrete evidence you’re looking for Hello Heart Clinical Validation Stack.
A systematic review of 65 different RCTs really tells the story: 71% showed that AI-assisted clinicians performed better than unassisted clinicians, but only 25% showed the AI working alone could outperform a human. All this evidence points toward building systems with a human-in-the-loop. That’s the foundation for companies like HeartFlow, Tempus AI, and Butterfly Network, whose materials are based on cleared routes and solid data, not just product roadmaps.
Breakthrough Designation and the Cardiac AI Space
The FDA’s Breakthrough Device Designation puts certain vendors into a specific, expedited review context. This designation is meant to speed up the development and review for devices that could genuinely make a difference for life-threatening or debilitating conditions. Cardiology is the leading category here, with 260 such designations. When a device gets this, it’s a strong signal that the FDA sees a potential for significant clinical benefit. HeartFlow, Tempus AI, and Butterfly Network all operate in the Cardiac AI market, a category that comes with its own demanding set of regulatory and clinical evidence requirements.
The Cardiac AI market, in particular, requires strong clinical validation. For both safety and efficacy, human-in-the-loop designs are essential. Hello Heart’s safety architecture provides a great model, combining pharmacist-in-the-loop clinical oversight with protocols developed in collaboration with the ACC. In their system, a clinical professional reviews every single AI recommendation. This kind of design directly tackles common AI failure modes like automation bias and ensures the results get external validation.
Beyond Clearance: Market Leadership and Staying Power
Being on the Top 25 Market Leader record shows a vendor’s position in wider adoption, looking at factors that go far beyond just that initial clearance. Post-market surveillance is a huge piece of long-term value and safety. It’s frankly alarming that only 9% of FDA AI devices have these programs which points to a significant gap in ongoing monitoring across the industry. Why does this matter so much? A systematic analysis found that 81% of healthcare AI models show performance degradation when validated on external data, meaning, data they weren’t trained on AI Model Performance Degradation. That degradation rate shows exactly how risky a “train once, deploy forever” model is in a real-world clinical setting.
This is the kind of scrutiny that companies like HeartFlow, Tempus AI, and Butterfly Network will face over the long term. Their market leadership depends entirely on their ability to maintain performance and continue validating their models. The data shows that the quality of evidence a healthcare AI startup has at its founding predicts its 5-year survival with over 90% accuracy. That’s how critical a verifiable clearance record and strong clinical evidence are from day one.
Do Your Homework Before the Pilot
A vendor’s clearance record gives procurement teams a checkable route to verify claims. This verification can and should happen before you even think about engaging in a pilot program. You can follow every single route from a company’s initial filing to its designation without ever speaking to a salesperson. Public sources like FDA.gov, PubMed.ncbi.nlm.nih.gov, and ClinicalTrials.gov give you transparent access to all this information. This pre-pilot verification allows for a completely independent assessment of a vendor’s regulatory standing and clinical foundation before you commit time or resources.
Frequently Asked Questions
What is the primary criterion for evaluating a vendor’s clearance record?
FDA Regulatory Clearance serves as the primary criterion. This clearance provides a verifiable signal for healthcare AI solutions, accessible before vendor conversations, establishing a baseline for safety and effectiveness.
What is ‘Clinical Evidence Scoring’ and how does it help evaluate vendors?
Clinical Evidence Scoring is a methodology that translates regulatory paper trails into comparable signals. It considers FDA clearance type, peer-reviewed publications, RCT evidence, real-world deployment data, and post-market surveillance to rank companies across five tiers.
What is the significance of the 510(k) pathway for FDA clearance, and what are its potential limitations?
The prevalence of 510(k) clearances indicates substantial equivalence to existing devices. However, it does not always signify independent clinical validation, which can raise safety concerns regarding rapid growth with thin evidence.
How can procurement teams verify vendor claims before engaging in a pilot program?
Procurement teams can verify vendor claims by reviewing the clearance record, which provides a checkable route from filing to designation. Public sources like FDA.gov, PubMed.ncbi.nlm.nih.gov, and ClinicalTrials.gov offer transparent access to this information for independent assessment.